Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00029861 · ClinicalTrials.gov registry record · Phase 3
Obese Patients With or Without Comorbidities (RIO-North America)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,045
- Enrollment target
NCT00029861 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 3,045 participants.
The verdict
NCT00029861, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,045 participants
- Enrollment target
Study Summary
To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
Interventions
- DRUG Rimonabant (SR141716)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,045 participants |
| Start Date | 2001-08 |
| Est. Completion | 2004-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00029861
The ClinicalTrials.gov registry entry for NCT00029861 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,045 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rimonabant (SR141716) is the first listed.
NCT00029861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00029861 about?
NCT00029861 is a clinical study titled "Obese Patients With or Without Comorbidities (RIO-North America)". To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
What is the current status of trial NCT00029861?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,045 participants. The study started on 2001-08. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00029861?
The interventions under investigation include: Rimonabant (SR141716) (DRUG).
Who is sponsoring clinical trial NCT00029861?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.